Korea United Pharm. Inc.
18
2
2
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
5.6%
1 terminated/withdrawn out of 18 trials
90.9%
+4.4% vs industry average
28%
5 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
Role: collaborator
A Study to Evaluate the Safety and Pharmacokinetics of UI087 Compared to Coadministration of UIC202506, UIC202507 and UIC202508 in Healthy Adult Volunteers Under Fasting Conditions
Role: lead
A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers
Role: lead
Bioequivalence Study Between UI009 and UIC202005 in Healthy Subjects
Role: lead
Drug-drug Interaction Study Between UIC201603, and UIC201604
Role: lead
A Study to Compare PK, PD and Safety of UI058 and UIC202004 in Healthy Subjects
Role: lead
A Study to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UI059 and UIC202201
Role: lead
A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects
Role: lead
A Clinical Study to Evaluate the Safety and the Pharmacokinetics of UI068 in Healthy Adult Volunteers Under Fed Conditions
Role: lead
Drug-drug Interaction Study Between UIC201601 and UIC201602
Role: lead
Study to Evaluate the Safety and PK of UI018
Role: lead
Arformoterol/Budesonide for COVID-19
Role: lead
Safety and Efficacy of Cefecin Tab. in Patients With Acute Sinusitis
Role: lead
Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia
Role: lead
A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of UI15AML055MT and Amosartan® Tablet 5/50 mg After a Single Oral Administration in Healthy Male Volunteers
Role: lead
Safety and Efficacy of KALOMIN™ Tab. in Patients With Acute Bronchitis
Role: lead
Study of Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)for Treatment of Post Operative Nausea and Vomiting
Role: collaborator
Pharmacokinetics and Food Effect of Sarpogrelate HCl CR Formulation in Comparison to Immediate-release Formulation
Role: lead
All 18 trials loaded